Fig. 1

High-dose PLX5622 pretreatment causes poor outcome in LPS and PCI induced systemic inflammation. A Timeline of experiment: mice were randomized to AIN or PLX5622 (1200 ppm) treatment seven days prior to PCI induction. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus at day 0 following AIN or PLX5622 treatment (n = 3 animals/group; n = 3 images/animal, Student’s t-test). Representative confocal overview images of microglia in the CA1 region after pretreatment with either AIN or high-dose PLX5622 (1200 ppm) on day 0. Scale bar 200 µm. C Kaplan–Meier analysis of PCI induced sepsis following AIN or high-dose PLX5622 treatment for seven days (AIN: PCI: n = 21 animals/group, PLX5622: PCI: n = 6 animals/group, log-rank test). D Representative photograph of cerebral microbleeds in mice pretreated with high-dose PLX5622 for seven days followed by PCI induction. E Timeline of experiment: mice were randomized to AIN or high-dose PLX5622 (1200 ppm) treatment seven days prior to induction of systemic inflammation by LPS. F Kaplan–Meier analysis of LPS induced systemic inflammation following AIN and high-dose PLX5622 pretreatment for 7 consecutive days (AIN: LPS: n = 14 animals/group and PLX5622: LPS: n = 6 animals/group). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded